Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients

To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Lin, Liang, Yi-Hsin, Tsai, Jia-Huei, Liau, Jau-Yu, Liang, Jin-Tung, Lin, Been-Ren, Hung, Ji-Shiang, Lin, Liang-In, Tseng, Li-Hui, Chang, Yih-Leong, Yeh, Kun-Huei, Cheng, Ann-Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913571/
https://www.ncbi.nlm.nih.gov/pubmed/24505265
http://dx.doi.org/10.1371/journal.pone.0086789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913571/
https://www.ncbi.nlm.nih.gov/pubmed/24505265
http://dx.doi.org/10.1371/journal.pone.0086789

Ejemplares similares